Dr Reddy’s Q3 net profit rises
Dr Reddy’s Laboratories posted a consolidated net profit of Rs 27.9 crore for the third quarter ended December 31, 2020. The company had posted a net loss of Rs 538.4 crore during the same period of the previous fiscal.
Total revenue from operations stood at Rs 4,941.9 crore for the quarter under review, up 12.38%. During the third quarter ended December 31, 2019, the total revenue from operations was at Rs 4,397.1 crore.
EBITDA came at Rs 1,185 crore and EBITDA margin stood 24% for Q3FY21.
The gross margin stood at 53.8% against 54.1% YoY and 53.9% QoQ.
SGNA expenses rose 14% YoY and 10% QoQ to Rs 1,439 crore. R&D expenses stood at Rs 411 crore for the quarter.
The drug maker continued to gain growth momentum in revenue while maintaining EBITDA (earnings before interest, taxes, depreciation and amortisation) margins.
However, its profit growth was impacted due to trigger-based impairment charge taken on a few acquired products.
It is progressing well on phase 3 clinical trials for Sputnik V vaccine in India.
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.